This document provides an overview of monoclonal antibodies and their importance. It begins with definitions of the immune system and its components. It then discusses the anatomy and cells of the immune system, and how it functions through both humoral and cell-mediated responses. The document explains the production of monoclonal antibodies using hybridoma technology. It lists FDA-approved monoclonal antibodies and their applications in diagnosis, treatment of diseases like cancer and infection. The market for monoclonal antibodies is projected to reach $26 billion by the end of the decade due to their role in driving the biotechnology industry and success in developing new therapies.
In this section of the coronavirus pandemic series, we discuss the need for an effective COVID-19 vaccine to return to full normalcy. The slides would give a brief overview on how our immune systems work, and how a vaccine would train our immune system to recognize and fight the infection. Current vaccine platform technologies will be compared, and upcoming candidates will be highlighted for newer-generation vaccines. We'll also discuss in-depth on factors involving vaccine manufacturing, hesitancy & acceptance, and contingencies. The market capitalization of pharma companies involved in the development of the coronavirus vaccine will also be compared.
Pharmacokinetics study influences the
Decided route of administration for a specific medication
the amount and the frequency of each dose and its dosing intervals.
Download Global cancer immunotherapy market outlook 2020KuicK Research
\"Global Cancer Immunotherapy Market Outlook 2020\" Report Highlight:
Introduction & Classification of Cancer Immunotherapy
Global Cancer Immunotherapy Pipeline by Company, Indication & Phase
Marketed Cancer Immunotherapies Clinical Insight & Patent Analysis by Company & Indication
Global Cancer Immunotherapy Pipeline: 1834 Drugs
Marketed Cancer Immunotherapies: 113 Drugs
Cancer Monoclonal Antibodies Pipeline: 622 Cancer mAb
Cancer Vaccines Pipeline: 312 Vaccines
Marketed Cancer mAb: 36 mAb
Marketed Cancer Vaccines: 12 Vaccines
In this section of the coronavirus pandemic series, we discuss the need for an effective COVID-19 vaccine to return to full normalcy. The slides would give a brief overview on how our immune systems work, and how a vaccine would train our immune system to recognize and fight the infection. Current vaccine platform technologies will be compared, and upcoming candidates will be highlighted for newer-generation vaccines. We'll also discuss in-depth on factors involving vaccine manufacturing, hesitancy & acceptance, and contingencies. The market capitalization of pharma companies involved in the development of the coronavirus vaccine will also be compared.
Pharmacokinetics study influences the
Decided route of administration for a specific medication
the amount and the frequency of each dose and its dosing intervals.
Download Global cancer immunotherapy market outlook 2020KuicK Research
\"Global Cancer Immunotherapy Market Outlook 2020\" Report Highlight:
Introduction & Classification of Cancer Immunotherapy
Global Cancer Immunotherapy Pipeline by Company, Indication & Phase
Marketed Cancer Immunotherapies Clinical Insight & Patent Analysis by Company & Indication
Global Cancer Immunotherapy Pipeline: 1834 Drugs
Marketed Cancer Immunotherapies: 113 Drugs
Cancer Monoclonal Antibodies Pipeline: 622 Cancer mAb
Cancer Vaccines Pipeline: 312 Vaccines
Marketed Cancer mAb: 36 mAb
Marketed Cancer Vaccines: 12 Vaccines
Global cancer immunotherapy market outlook 2020KuicK Research
"Global Cancer Immunotherapy Market Outlook 2020" Report Highlight:
Introduction & Classification of Cancer Immunotherapy
Global Cancer Immunotherapy Pipeline by Company, Indication & Phase
Marketed Cancer Immunotherapies Clinical Insight & Patent Analysis by Company & Indication
Global Cancer Immunotherapy Pipeline: 1834 Drugs
Marketed Cancer Immunotherapies: 113 Drugs
Cancer Monoclonal Antibodies Pipeline: 622 Cancer mAb
Cancer Vaccines Pipeline: 312 Vaccines
Marketed Cancer mAb: 36 mAb
Marketed Cancer Vaccines: 12 Vaccines
Download Global cancer immunotoxins market & clinical pipeline insight 2020KuicK Research
“Global Cancer Immunotoxins Market & Clinical Pipeline Insight 2020” Report Highlights:
Introduction to Immunotoxins
Cancer Immunotoxins Therapy Analysis
Advantages of Immunotoxins upon other Anticancerous Drugs
Applications of Immunotoxins to Multiple Cancer Therapies
Global Cancer Immunotoxins Market Future Prospects
Global Cancer Immunotoxins Clinical Pipeline by Company, Indication & Phase
Global Cancer Immunotoxins Clinical Pipeline: 52 Cancer Immunotoxins
Majority Cancer Immunotoxins in Preclinical Phase: 21 Drugs
Global cancer immunotherapy market outlook 2020KuicK Research
"Global Cancer Immunotherapy Market Outlook 2020" Report Highlight:
Introduction & Classification of Cancer Immunotherapy
Global Cancer Immunotherapy Pipeline by Company, Indication & Phase
Marketed Cancer Immunotherapies Clinical Insight & Patent Analysis by Company & Indication
Global Cancer Immunotherapy Pipeline: 1834 Drugs
Marketed Cancer Immunotherapies: 113 Drugs
Cancer Monoclonal Antibodies Pipeline: 622 Cancer mAb
Cancer Vaccines Pipeline: 312 Vaccines
Marketed Cancer mAb: 36 mAb
Marketed Cancer Vaccines: 12 Vaccines
Immune System Part II:The Innate Immune SystemFysiMack
Innate, or nonspecific, immunity is the defense system with which you were born. It protects you against all antigens. Innate immunity involves barriers that keep harmful materials from entering your body. These barriers form the first line of defense in the immune response
Antibiotic resistance, the modern war against microbesIsaac Majiok Kok
The focus of this ppt is mainly on the human body, the immune system, antibiotic resistance, the cause and the solution to antibiotic resistance and the future of human medicine
Immunity
It can be defined as the resistance to disease, specifically to infectious disease or pathogens. The term “immune” is derived from the Latin word “immunis” that is exempt from charges. In medical term, it refers to the being protected from infectious pathogens.
Immune system
It is adaptive defense system which is able to generate a variety of cell and molecules capable of specifically recognizing and eliminating a variety of limitless foreign invaders into the system.
In 1975 Georges Kohler and Milstein succeeded in making fusions of myeloma cell lines with B cells to create hybridomas that could produce antibodies.
antibody
Also known as immunoglobulin is a large, Y shaped glycoprotein produced mainly by plasma cells that is used by the immune system to neutralize pathogens.
monoclonal antibodies
Antibodies that are made by identical immune cells that are clones of a unique parent cell.
polyclonal antibodies
A polyclonal antibodies represents a collection of antibodies from different B cells that recognize multiple epitopes on the same antigen.
Global cancer immunotherapy market outlook 2020KuicK Research
"Global Cancer Immunotherapy Market Outlook 2020" Report Highlight:
Introduction & Classification of Cancer Immunotherapy
Global Cancer Immunotherapy Pipeline by Company, Indication & Phase
Marketed Cancer Immunotherapies Clinical Insight & Patent Analysis by Company & Indication
Global Cancer Immunotherapy Pipeline: 1834 Drugs
Marketed Cancer Immunotherapies: 113 Drugs
Cancer Monoclonal Antibodies Pipeline: 622 Cancer mAb
Cancer Vaccines Pipeline: 312 Vaccines
Marketed Cancer mAb: 36 mAb
Marketed Cancer Vaccines: 12 Vaccines
Download Global cancer immunotoxins market & clinical pipeline insight 2020KuicK Research
“Global Cancer Immunotoxins Market & Clinical Pipeline Insight 2020” Report Highlights:
Introduction to Immunotoxins
Cancer Immunotoxins Therapy Analysis
Advantages of Immunotoxins upon other Anticancerous Drugs
Applications of Immunotoxins to Multiple Cancer Therapies
Global Cancer Immunotoxins Market Future Prospects
Global Cancer Immunotoxins Clinical Pipeline by Company, Indication & Phase
Global Cancer Immunotoxins Clinical Pipeline: 52 Cancer Immunotoxins
Majority Cancer Immunotoxins in Preclinical Phase: 21 Drugs
Global cancer immunotherapy market outlook 2020KuicK Research
"Global Cancer Immunotherapy Market Outlook 2020" Report Highlight:
Introduction & Classification of Cancer Immunotherapy
Global Cancer Immunotherapy Pipeline by Company, Indication & Phase
Marketed Cancer Immunotherapies Clinical Insight & Patent Analysis by Company & Indication
Global Cancer Immunotherapy Pipeline: 1834 Drugs
Marketed Cancer Immunotherapies: 113 Drugs
Cancer Monoclonal Antibodies Pipeline: 622 Cancer mAb
Cancer Vaccines Pipeline: 312 Vaccines
Marketed Cancer mAb: 36 mAb
Marketed Cancer Vaccines: 12 Vaccines
Immune System Part II:The Innate Immune SystemFysiMack
Innate, or nonspecific, immunity is the defense system with which you were born. It protects you against all antigens. Innate immunity involves barriers that keep harmful materials from entering your body. These barriers form the first line of defense in the immune response
Antibiotic resistance, the modern war against microbesIsaac Majiok Kok
The focus of this ppt is mainly on the human body, the immune system, antibiotic resistance, the cause and the solution to antibiotic resistance and the future of human medicine
Immunity
It can be defined as the resistance to disease, specifically to infectious disease or pathogens. The term “immune” is derived from the Latin word “immunis” that is exempt from charges. In medical term, it refers to the being protected from infectious pathogens.
Immune system
It is adaptive defense system which is able to generate a variety of cell and molecules capable of specifically recognizing and eliminating a variety of limitless foreign invaders into the system.
In 1975 Georges Kohler and Milstein succeeded in making fusions of myeloma cell lines with B cells to create hybridomas that could produce antibodies.
antibody
Also known as immunoglobulin is a large, Y shaped glycoprotein produced mainly by plasma cells that is used by the immune system to neutralize pathogens.
monoclonal antibodies
Antibodies that are made by identical immune cells that are clones of a unique parent cell.
polyclonal antibodies
A polyclonal antibodies represents a collection of antibodies from different B cells that recognize multiple epitopes on the same antigen.
Instructions for Submissions thorugh G- Classroom.pptxJheel Barad
This presentation provides a briefing on how to upload submissions and documents in Google Classroom. It was prepared as part of an orientation for new Sainik School in-service teacher trainees. As a training officer, my goal is to ensure that you are comfortable and proficient with this essential tool for managing assignments and fostering student engagement.
Macroeconomics- Movie Location
This will be used as part of your Personal Professional Portfolio once graded.
Objective:
Prepare a presentation or a paper using research, basic comparative analysis, data organization and application of economic information. You will make an informed assessment of an economic climate outside of the United States to accomplish an entertainment industry objective.
Acetabularia Information For Class 9 .docxvaibhavrinwa19
Acetabularia acetabulum is a single-celled green alga that in its vegetative state is morphologically differentiated into a basal rhizoid and an axially elongated stalk, which bears whorls of branching hairs. The single diploid nucleus resides in the rhizoid.
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...Levi Shapiro
Letter from the Congress of the United States regarding Anti-Semitism sent June 3rd to MIT President Sally Kornbluth, MIT Corp Chair, Mark Gorenberg
Dear Dr. Kornbluth and Mr. Gorenberg,
The US House of Representatives is deeply concerned by ongoing and pervasive acts of antisemitic
harassment and intimidation at the Massachusetts Institute of Technology (MIT). Failing to act decisively to ensure a safe learning environment for all students would be a grave dereliction of your responsibilities as President of MIT and Chair of the MIT Corporation.
This Congress will not stand idly by and allow an environment hostile to Jewish students to persist. The House believes that your institution is in violation of Title VI of the Civil Rights Act, and the inability or
unwillingness to rectify this violation through action requires accountability.
Postsecondary education is a unique opportunity for students to learn and have their ideas and beliefs challenged. However, universities receiving hundreds of millions of federal funds annually have denied
students that opportunity and have been hijacked to become venues for the promotion of terrorism, antisemitic harassment and intimidation, unlawful encampments, and in some cases, assaults and riots.
The House of Representatives will not countenance the use of federal funds to indoctrinate students into hateful, antisemitic, anti-American supporters of terrorism. Investigations into campus antisemitism by the Committee on Education and the Workforce and the Committee on Ways and Means have been expanded into a Congress-wide probe across all relevant jurisdictions to address this national crisis. The undersigned Committees will conduct oversight into the use of federal funds at MIT and its learning environment under authorities granted to each Committee.
• The Committee on Education and the Workforce has been investigating your institution since December 7, 2023. The Committee has broad jurisdiction over postsecondary education, including its compliance with Title VI of the Civil Rights Act, campus safety concerns over disruptions to the learning environment, and the awarding of federal student aid under the Higher Education Act.
• The Committee on Oversight and Accountability is investigating the sources of funding and other support flowing to groups espousing pro-Hamas propaganda and engaged in antisemitic harassment and intimidation of students. The Committee on Oversight and Accountability is the principal oversight committee of the US House of Representatives and has broad authority to investigate “any matter” at “any time” under House Rule X.
• The Committee on Ways and Means has been investigating several universities since November 15, 2023, when the Committee held a hearing entitled From Ivory Towers to Dark Corners: Investigating the Nexus Between Antisemitism, Tax-Exempt Universities, and Terror Financing. The Committee followed the hearing with letters to those institutions on January 10, 202
A Strategic Approach: GenAI in EducationPeter Windle
Artificial Intelligence (AI) technologies such as Generative AI, Image Generators and Large Language Models have had a dramatic impact on teaching, learning and assessment over the past 18 months. The most immediate threat AI posed was to Academic Integrity with Higher Education Institutes (HEIs) focusing their efforts on combating the use of GenAI in assessment. Guidelines were developed for staff and students, policies put in place too. Innovative educators have forged paths in the use of Generative AI for teaching, learning and assessments leading to pockets of transformation springing up across HEIs, often with little or no top-down guidance, support or direction.
This Gasta posits a strategic approach to integrating AI into HEIs to prepare staff, students and the curriculum for an evolving world and workplace. We will highlight the advantages of working with these technologies beyond the realm of teaching, learning and assessment by considering prompt engineering skills, industry impact, curriculum changes, and the need for staff upskilling. In contrast, not engaging strategically with Generative AI poses risks, including falling behind peers, missed opportunities and failing to ensure our graduates remain employable. The rapid evolution of AI technologies necessitates a proactive and strategic approach if we are to remain relevant.
Embracing GenAI - A Strategic ImperativePeter Windle
Artificial Intelligence (AI) technologies such as Generative AI, Image Generators and Large Language Models have had a dramatic impact on teaching, learning and assessment over the past 18 months. The most immediate threat AI posed was to Academic Integrity with Higher Education Institutes (HEIs) focusing their efforts on combating the use of GenAI in assessment. Guidelines were developed for staff and students, policies put in place too. Innovative educators have forged paths in the use of Generative AI for teaching, learning and assessments leading to pockets of transformation springing up across HEIs, often with little or no top-down guidance, support or direction.
This Gasta posits a strategic approach to integrating AI into HEIs to prepare staff, students and the curriculum for an evolving world and workplace. We will highlight the advantages of working with these technologies beyond the realm of teaching, learning and assessment by considering prompt engineering skills, industry impact, curriculum changes, and the need for staff upskilling. In contrast, not engaging strategically with Generative AI poses risks, including falling behind peers, missed opportunities and failing to ensure our graduates remain employable. The rapid evolution of AI technologies necessitates a proactive and strategic approach if we are to remain relevant.
2024.06.01 Introducing a competency framework for languag learning materials ...Sandy Millin
http://sandymillin.wordpress.com/iateflwebinar2024
Published classroom materials form the basis of syllabuses, drive teacher professional development, and have a potentially huge influence on learners, teachers and education systems. All teachers also create their own materials, whether a few sentences on a blackboard, a highly-structured fully-realised online course, or anything in between. Despite this, the knowledge and skills needed to create effective language learning materials are rarely part of teacher training, and are mostly learnt by trial and error.
Knowledge and skills frameworks, generally called competency frameworks, for ELT teachers, trainers and managers have existed for a few years now. However, until I created one for my MA dissertation, there wasn’t one drawing together what we need to know and do to be able to effectively produce language learning materials.
This webinar will introduce you to my framework, highlighting the key competencies I identified from my research. It will also show how anybody involved in language teaching (any language, not just English!), teacher training, managing schools or developing language learning materials can benefit from using the framework.
The French Revolution, which began in 1789, was a period of radical social and political upheaval in France. It marked the decline of absolute monarchies, the rise of secular and democratic republics, and the eventual rise of Napoleon Bonaparte. This revolutionary period is crucial in understanding the transition from feudalism to modernity in Europe.
For more information, visit-www.vavaclasses.com
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdfTechSoup
In this webinar you will learn how your organization can access TechSoup's wide variety of product discount and donation programs. From hardware to software, we'll give you a tour of the tools available to help your nonprofit with productivity, collaboration, financial management, donor tracking, security, and more.
Honest Reviews of Tim Han LMA Course Program.pptxtimhan337
Personal development courses are widely available today, with each one promising life-changing outcomes. Tim Han’s Life Mastery Achievers (LMA) Course has drawn a lot of interest. In addition to offering my frank assessment of Success Insider’s LMA Course, this piece examines the course’s effects via a variety of Tim Han LMA course reviews and Success Insider comments.
Synthetic Fiber Construction in lab .pptxPavel ( NSTU)
Synthetic fiber production is a fascinating and complex field that blends chemistry, engineering, and environmental science. By understanding these aspects, students can gain a comprehensive view of synthetic fiber production, its impact on society and the environment, and the potential for future innovations. Synthetic fibers play a crucial role in modern society, impacting various aspects of daily life, industry, and the environment. ynthetic fibers are integral to modern life, offering a range of benefits from cost-effectiveness and versatility to innovative applications and performance characteristics. While they pose environmental challenges, ongoing research and development aim to create more sustainable and eco-friendly alternatives. Understanding the importance of synthetic fibers helps in appreciating their role in the economy, industry, and daily life, while also emphasizing the need for sustainable practices and innovation.
1. I. Overview: - The Immune System
II. Introduction: - Monoclonal
Antibodies
2. • The Perfect World • The Real World
COL
D
FL
U
CHICKEN
POX
STOMAC
H UPSET
HELP
ME !
HELP !
HELP
ME!
3. THE IMMUNE SYSTEM
DEFINITION: - The integrated body system of organs, tissues,
cells & cell products that differentiates self from non – self &
neutralizes potentially pathogenic organisms.
(The American Heritage Stedman's Medical Dictionary)
The Latin term “IMMUNIS” means EXEMPT, referring to
protection against foreign agents.
The Immune System consists of
1. Innate Immunity Primary Response
2. Acquired Immunity Secondary Response
6. BECOMES
FUNCTIONING OF THE IMMUNE SYSTEM
HUMORAL (ANTIBODY MEDIATED) IMMUNE RESPONSE CELL MEDIATED IMMUNE RESPONSE
ANTIGEN (1ST EXPOSURE)
ANTIGENS
DISPLAYED
BY
INFECTED
CELLS
ACTIVATE
CYTOTOXIC
T CELL
GIVES RISE TO
ACTIVE
CYTOTOXIC T
CELL
ENGULFED BY
STIMULATES
MACROPHAGE
APC
HELPER
T CELLS STIMULATES
MEMORY
HELPER T
CELLS
MEMORY
T CELLS
MEMORY
B CELLS
PLASMA
CELLS
STIMULATES STIMULATES
B CELLS
FREE
ANTIGENS
DIRECTLY
ACTIVATE
STIMULATES
GIVES RISE TO
SECRETE ANTIBODIES
STIMULATES
ANTIGEN (2nd EXPOSURE)
STIMULATES
7. IMMUNOTHERAPY
Treatment of the disease by Inducing, Enhancing or
Suppressing the Immune System.
Active Immunotherapy: -
It stimulates the body’s own
immune system to fight the
disease.
Passive Immunotherapy: -
It does not rely on the body to
attack the disease, instead they
use the immune system
components ( such as
antibodies) created outside the
body.
11. FDAAPPROVED MONOCLONAL ANTIBODIES
H
2003
Psoriasis
Raptiva™
Genentech/Xoma
C
1997
Non-Hodgkin’s Lymphoma
Rituxan®
BiogenIdec/Genentech/Roche
M
2003
Non-Hodgkin’s Lymphoma
Bexxar®
Corixa/GlaxoSmithKline
C
2004
Colorectal Cancer
Erbitux ™
BMS/ImClone Systems
H
2003
Asthma
Xolair®
Novartis/Genentech/Tanox
PD
2002
Rheumatoid Arthritis
Humira™
Abbott/CAT
H
2001
Chronic Lymphocytic
Leukemia
Campath®
Schering /ILEX Oncology
H
2000
Acute Myleoid Leukemia
Mylotarg™
Wyeth
C
1998
Acute Transplant Rejection
Simulect®
Novartis
C
1998
Crohn’s, Rheumatoid Arthritis
Remicade®
J & J
H
H
1998
2004
Breast Cancer
Colorectal Cancer
Herceptin®
Avastin ®
Genentech/Roche
H
1998
Viral Respiratory Disease
Synagis®
MedImmune/Abbott
H
1997
Acute Transplant Rejection
Zenapax®
PDLI
M
2002
Non-Hodgkin’s Lymphoma
Zevalin™
BiogenIdec
C
1994
Acute Cardiac Conditions
ReoPro®
J&J/Eli Lilly
M
1986
Organ Transplant Rejection
Orthoclone-OKT®
Ortho Biotech
Antibody
Type (2)
Date of
FDA
Approval
Indications
Name of Product(1)
Company Name
12. Applications of Monoclonal
Antibodies
• Diagnostic Applications
Biosensors & Microarrays
• Therapeutic Applications
Transplant rejection Muronomab-CD3
Cardiovascular disease Abciximab
Cancer Rituximab
Infectious Diseases Palivizumab
Inflammatory disease Infliximab
• Clinical Applications
Purification of drugs, Imaging the target
• Future Applications
Fight against Bioterrorism
13. Market Analysis & Forecast
• Industry participants forecast of the market vary
widely, however, a consensus is emerging that
the market should reach US$26 billion by the end
of the decade. This is a conservative estimate
implying an average annual growth rate of 18%.
• By 2008, mAbs should account for 32 percent of
all revenue in the biotech market
• 100 mAb Expected By 2010
• mAb contributing to the in vitro diagnostics
market expected to be worth $34 Billion this year
14. Why should we be interested ?
• mAbs drive the development of multibillion dollar
biotechnology industry.
• Many of the leading pharmaceutical companies
have entered the mAb sector, attracted by quicker
and less costly development, higher success rates,
premium pricing, and a potentially reduced threat
from generics
• The outlook for monoclonal antibody therapeutics
is healthy. The ongoing success of existing
products, combined with a bulging pipeline of new
products awaiting approval and limited generic
erosion, point towards robust growth in this
segment
15. PAUL EHRLICH
“…. I TRUST, THAT
WE NO LONGER
FIND OURSELVES
LOST ON A
BOUNDLESS SEA,
BUT THAT WE HAVE
ALREADY CAUGHT
A DISTINCT
GLIMPSE OF THE
LAND WHERE WE
HOPE, NAY, WHICH
WE EXPECT, WILL
TEILD RICH
TREASURES FOR
BIOLOGY AND
THERAPEUTICS”
